1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …

Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

Abstract Background/Objective Before approval of andexanet alfa, off‐label treatment with 4‐
factor prothrombin complex concentrate (4F‐PCC) was often utilized for the management of …

Background: Since the approval of the oral factor Xa inhibitors, there have been concerns
regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage …

Early recognition of coagulopathy is necessary for its prompt correction and successful
management. Novel approaches, such as point-of-care testing (POC) and administration of …

For more than a decade, US laboratories have failed to implement solutions to help their
clinicians in managing complex situations or patients on direct oral anticoagulants (DOACs) …

Importance Intracerebral hemorrhage (ICH) associated with direct oral anticoagulant
(DOAC) use carries extremely high morbidity and mortality. The clinical effectiveness of …

Anticoagulation is key to the treatment/prevention of thromboembolic events. The primary
complication of anticoagulation is serious or life-threatening hemorrhage, which may …

Background Atrial fibrillation (AF) is the most common arrhythmia and its management in
cirrhosis can be challenging due to the altered hepatic metabolism of medications and …